Today: 21 March 2026
Subscribe
Browse Category

Pharmaceuticals 9 January 2026 - 11 January 2026

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines shares jumped 10.7% to $118.64 Friday amid reports Merck is in talks to acquire the company for up to $32 billion, according to the Financial Times. Trading volume hit 20.8 million shares. AbbVie denied it was in discussions after an earlier report, sending Revolution’s stock down 11.5% after hours. The FDA granted Breakthrough Therapy status to Revolution’s lung cancer drug candidate.
11 January 2026
··
Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk shares rose 3% to 381.45 crowns in Copenhagen after Amazon Pharmacy began selling its new Wegovy weight-loss pill in the U.S. The pill, approved by the FDA in December, puts Novo ahead of Eli Lilly in the obesity pill market. About 8.95 million shares traded Friday, with prices ranging from 369.0 to 389.8 crowns. Novo will report full-year results on Feb. 4.
10 January 2026
··
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie shares fell 1.8% to $220.08 Friday after the company cut its Q4 and 2025 profit forecasts, citing a $1.3 billion charge for acquired R&D and milestone expenses. The company denied rumors of takeover talks with Revolution Medicines. AbbVie will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings on Feb. 4.
10 January 2026
···
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson shares fell 0.7% to $204.39 Friday after the company agreed to lower U.S. drug prices in exchange for tariff exemptions, with terms undisclosed. J&J will join the TrumpRx.gov platform and said it plans two new U.S. manufacturing sites. The S&P 500 rose 0.65%. Investors await the JPMorgan healthcare conference and J&J’s Jan. 21 earnings call.
10 January 2026
··
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly shares fell 2% to $1,063.56 Friday, extending a two-day decline and lagging the broader market. The drop followed late-stage trial results for a Zepbound-Taltz drug combo and news of a $1.2 billion deal to buy Ventyx Biosciences. A Form 4 filing showed Lilly Endowment sold 292,148 shares on January 7. Lilly will present at the J.P. Morgan Healthcare Conference on January 13.
10 January 2026
···
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers Health shares dropped 6.4% to $31.69 Friday, extending a two-day slide to 11% after Amazon Pharmacy entered the Wegovy weight-loss pill market. BofA cut its price target and kept an Underperform rating, citing high 2026 estimates. The stock closed below key moving averages and neared oversold levels. The FDA previously warned the company over marketing claims for compounded weight-loss drugs.
10 January 2026
··
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio filed a motion to dismiss part of GSK’s claim in a Delaware court dispute over royalties from cancer drug Jemperli. The court is expected to hear the motion by early March, with trial set for July. GSK ADRs closed up 0.3% at $50.39 in New York; London shares slipped 0.26% to 1,886 pence. Investors await GSK’s Jan. 13 conference appearance and Feb. 4 results.
10 January 2026
····
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
10 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon shares rose 0.4% after hours to $247.33 following news that Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill at $25 per month for insured customers and $149 for cash-pay. The pill, approved by the FDA in December, will be shipped to all 50 states. Investors await Amazon’s Q4 results on Feb. 5 and a key EU digital proposal on Jan. 20.
9 January 2026
····
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers shares dropped 5.3% to $32.06 after Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill. Bank of America cut its price target on Hims, citing margin and spending risks for 2026. The stock fell from an intraday high of $34.35. Investors are watching for signs of pricing pressure and updated forecasts ahead of Hims’ next earnings report.
9 January 2026
··
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
1 … 14 15 16 17 18 … 38

Stock Market Today

  • TD1.AX TALi Digital plunges 16.67% amid liquidity concerns and sector weakness
    March 20, 2026, 11:34 PM EDT. TD1.AX shares of TALi Digital Limited fell 16.67% intraday to A$0.04 on March 21, 2026, marking significant losses for the small-cap healthcare tech stock. Trading volume hit 67,918 shares, below average, highlighting limited liquidity and sharp price swings. The company's earnings report shows ongoing losses with an EPS of -0.02 and weak revenue growth, intensifying investor concerns amid a pressured ASX healthcare sector. Financial ratios indicate a stable liquidity cushion but stretched receivables and negative free cash flow point to operational risks. Technical indicators reveal the stock is oversold, with forecasts suggesting potential upside of up to 66% over 12 months, though risks persist given thin trading and negative margins.
Go toTop